Method, composition and kit for detecting human B-type natriuretic peptide or precursor or degradation product thereof

By identifying the combination of monoclonal antibodies in the amino acid regions of positions 17 to 24 and positions 5 to 13 of hBNP, hBNP was detected by latex agglutination method, which solved the steric hindrance and terminal degradation problems between latex particles immobilized by the antibody, and improved the detection Efficiency and sensitivity reduce costs.

CN118946807APending Publication Date: 2024-11-12DENKA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029169.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-31
Filing Date
2023-03-28
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, when detecting human B-type natriuretic peptide (hBNP), latex agglutination method leads to low detection efficiency and high cost chemiluminescence due to the steric hindrance between latex particles immobilized by the antibody. The law is hard to replace.

Method used

The combination of monoclonal antibodies that recognize the amino acid regions of positions 17 to 24 and positions 5 to 13 of hBNP is used to detect hBNP by latex agglutination method to reduce the impact of steric hindrance and resist terminal degradation, and improve detection efficiency and sensitivity.

Benefits of technology

It realizes efficient detection under the influence of suppressing steric hindrance and terminal degradation, reduces detection cost, and improves the detection sensitivity of latex agglutination method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946807A_ABST
    Figure CN118946807A_ABST
Patent Text Reader

Abstract

A method for detecting hBNP or a precursor or degradation product thereof in a sample according to one aspect of the present invention comprises a step for using a monoclonal antibody or antigen-binding fragment thereof that recognizes the 17-24-th amino acid region in the amino acid sequence represented by SEQ ID NO: 1, and a step for recognizing the 5-th amino acid region in the amino acid sequence represented by SEQ ID NO: 1, and a step for recognizing the 5-th amino acid region in the amino acid sequence represented by SEQ ID NO: 1. The present invention relates to a method for detecting hBNP or a precursor or degradation product thereof in a sample by latex agglutination, the hBNP being a precursor of hproBNP and the degradation product of hBNP being a degradation product comprising the amino acid regions at positions 5-24 in the amino acid sequence represented by SEQ ID NO: 1, by using a monoclonal antibody or an antigen-binding fragment thereof that has the amino acid region at positions 13, in which the hBNP is a precursor of hproBNP and the degradation product of hBNP is a degradation product comprising the amino acid regions at positions 5-24 in the amino acid sequence represented by SEQ ID NO: 1. According to the present invention, hBNP can be detected by a latex agglutination method while suppressing the effects caused by steric hindrance between antibody-immobilized latex particles and degradation of the end of hBNP.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method, a composition and a kit for detecting human B-type natriuretic peptide or its precursor or degradation product. Background Art

[0002] Human B-type natriuretic peptide (hBNP, sequence number 1) is a circulating hormone biosynthesized and secreted in myocardial cells, and has diuretic effects, vasodilator effects, sympathetic nerve inhibition effects, cardiac hypertrophy inhibition effects, etc., and exerts its effects in a way that protects the myocardium. If a load is applied to the heart (especially the ventricle), first, human B-type natriuretic peptide precursor (hpreproBNP, sequence number 2), which is one of the precursors of hBNP, is expressed, cleaved into human B-type natriuretic peptide pro (hproBNP, sequence number 3) and subjected to post-translational modification. Then, the peptide bond between the 96th amino acid (arginine) and the 97th amino acid (serine) of hproBNP is cleaved by an enzyme to generate hBNP composed of amino acids (32 amino acids) from positions 97 to 128, achieving the expression of the above-mentioned pathological and physiological functions. Therefore, the expression level of hBNP increases according to the hyperload and pathological conditions of the heart, and is reflected in the blood concentration. Thus, hBNP expression is increased depending on the severity of heart failure, and hBNP in the blood increases, so hBNP is used as a diagnostic marker for heart failure.

[0003] It is said that the biological half-life of hBNP in vivo is about 20 minutes, and it is known to be an unstable molecule in plasma and serum. The degradation of hBNP caused by protease-type enzymes has been reported, for example, in non-patent document 1, it is recorded that the Arg30-Arg31 bond at the C-terminus and the N-terminal part (more specifically, the Pro2-Lys3 bond) are broken. It is reported that the degradation products of hBNP thus generated also maintain the above-mentioned pathophysiological functions. In view of the expression mechanism of the compensatory response to the symptoms of heart failure, it is important to evaluate the blood concentration of total hBNP, including hBNP degradation products, as a diagnostic indicator that helps to grasp the condition of heart failure and subsequent treatment (non-patent document 2).

[0004] In the detection of hBNP, a sandwich immunoassay using two or more monoclonal antibodies or polyclonal antibodies that recognize different epitopes of hBNP has been used. The so-called sandwich immunoassay is generally a method for quantitative and qualitative detection of antigens. In the method, antibodies that recognize different epitopes on the antigen are allowed to bind simultaneously, or one antibody is allowed to bind and then the other antibody is allowed to bind, and the antigen sandwiched by the two antibodies is detected.

[0005] As anti-hBNP antibodies that can be used in the existing sandwich immunoassay, antibodies that bind to various epitopes have been reported. For example, Patent Document 1 describes a monoclonal antibody that recognizes histidine (His32), which is the last amino acid of the C-terminal epitope (Lys27 to His32) of hBNP. As other epitopes on hBNP, Patent Document 2 describes Ser1 to Cys10, Val5 to Arg13, and Met15 to Gly25.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: Japanese Patent No. 2665850

[0009] Patent Document 2: Japanese Patent Application Publication No. 2007-169293

[0010] Non-patent literature

[0011] Non-patent document 1: Shimizu, et al. (2002) Clinica Chimica Acta 316: 129-135

[0012] Non-patent literature 2: Tomoko Ichiki, et al. Adv Clin Chem. 2013; 61: 1-31 Summary of the invention

[0013] Problems to be solved by the invention

[0014] The detection of hBNP requires high sensitivity, so in sandwich immunoassay, the method (chemiluminescent enzyme immunoassay) utilizing chemiluminescence is also used. Chemiluminescent reagent is expensive, so it is preferred if cheaper latex agglutination method can be utilized. However, in latex agglutination method, two kinds of antibodies need to be immobilized on latex particles respectively, and in addition, hBNP is a smaller peptide consisting of 32 amino acids, so when using existing anti-hBNP antibodies, antibody can not bind to antigen sometimes due to the steric hindrance between antibody-immobilized latex particles. In order to avoid the steric hindrance between antibody-immobilized latex particles, it is also considered to use the antibody of the C-terminal of recognition hBNP as one of the two antibodies, but in this case, it is impossible to detect the hBNP that the terminal is degraded in serum or plasma.

[0015] The present invention has been made in view of the above problems, and an object of the present invention is to detect hBNP by latex agglutination method while suppressing the influence of steric hindrance between antibody-immobilized latex particles and degradation of the terminal of hBNP.

[0016] Means for solving problems

[0017] The inventors of the present application have conducted in-depth research and found a new epitope hBNP17-24 (amino acid region of hBNP at positions 17 to 24: sequence number 4) in a region other than the N-terminal and C-terminal regions of hBNP that is susceptible to degradation based on proteases, and produced a new antibody that recognizes the epitope. Surprisingly, although hBNP17-24 is located near the known epitope hBNP5-13 (amino acid region of hBNP at positions 5 to 13: sequence number 5), by using a combination of an antibody that recognizes hBNP17-24 and an antibody that recognizes hBNP5-13, hBNP can be detected more efficiently using the latex agglutination method without being affected by steric hindrance. If it is a combination of the above antibodies, it is almost unaffected by the degradation of the N-terminal and C-terminal regions of hBNP. The inventors of the present application have completed the present invention based on the above insights.

[0018] One aspect of the present invention relates to a method for detecting human B-type natriuretic peptide or its precursor or degradation product in a sample, comprising: using a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region at positions 17 to 24 in the amino acid sequence shown in sequence number 1, and a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region at positions 5 to 13 in the amino acid sequence shown in sequence number 1, to detect human B-type natriuretic peptide or its precursor or degradation product in the sample by latex agglutination method, wherein the precursor of human B-type natriuretic peptide is pro-human B-type natriuretic peptide, and the degradation product of human B-type natriuretic peptide is a degradation product comprising the amino acid region at positions 5 to 24 in the amino acid sequence shown in sequence number 1.

[0019] One aspect of the present invention relates to a composition for detecting human B-type natriuretic peptide or its precursor or degradation, comprising: a first latex particle, on which a monoclonal antibody or its antigen-binding fragment recognizing the amino acid region at positions 17 to 24 in the amino acid sequence shown in sequence number 1 is immobilized; and a second latex particle, on which a monoclonal antibody or its antigen-binding fragment recognizing the amino acid region at positions 5 to 13 in the amino acid sequence shown in sequence number 1 is immobilized, wherein the precursor of human B-type natriuretic peptide is pro-human B-type natriuretic peptide, and the degradation product of human B-type natriuretic peptide is a degradation product comprising the amino acid region at positions 5 to 24 in the amino acid sequence shown in sequence number 1.

[0020] One aspect of the present invention relates to a kit for detecting human B-type natriuretic peptide or its precursor or degradation product, comprising: a first latex particle, on which a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region at positions 17 to 24 in the amino acid sequence shown in sequence number 1 is immobilized; and a second latex particle, on which a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region at positions 5 to 13 in the amino acid sequence shown in sequence number 1 is immobilized, the precursor of human B-type natriuretic peptide is human B-type natriuretic peptide pro, and the degradation product of human B-type natriuretic peptide is a degradation product containing the amino acid region at positions 5 to 24 in the amino acid sequence shown in sequence number 1.

[0021] Effects of the Invention

[0022] According to the present invention, hBNP can be detected by the latex agglutination method while suppressing the influence of steric hindrance between antibody-immobilized latex particles and degradation of the terminal of hBNP. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] [ Figure 1 ] is a diagram showing the results of epitope mapping of antibodies that specifically bind to hBNP.

[0024] [ Figure 2 ] is a graph showing the reactivity of different antibody pairs immobilized on latex particles with hBNP. Figure 2 (A) shows the results using an antibody pair that recognizes the amino acid regions at positions 5 to 13 and 17 to 24 of hBNP. Figure 2 (B) shows the results using an antibody pair that recognizes the amino acid regions at positions 5 to 13 and 14 to 20 of hBNP.

[0025] [ Figure 3 ] is a graph showing the effect of degradation of hBNP in plasma on the reactivity of different antibody pairs immobilized on latex particles with hBNP. Figure 3 (A) shows the results of using an antibody pair that recognizes the amino acid regions at positions 5 to 13 and 17 to 24 of hBNP. Figure 3 (B) shows the results using an antibody pair that recognizes the amino acid regions at positions 5 to 13 and 27 to 32 of hBNP. DETAILED DESCRIPTION

[0026] <Detection method>

[0027] One aspect of the present invention relates to a method for detecting human B-type natriuretic peptide (hBNP) or its precursor or degradation product in a sample, comprising: using a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region from positions 17 to 24 (sequence number 4) in the amino acid sequence shown in sequence number 1, and a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region from positions 5 to 13 (sequence number 5) in the amino acid sequence shown in sequence number 1, to detect human B-type natriuretic peptide or its precursor or degradation product in the sample by latex agglutination method.

[0028] The amino acid sequence shown in SEQ ID NO. 1 is the full-length amino acid sequence of hBNP, and the monoclonal antibody that recognizes the amino acid region at positions 17 to 24 in the amino acid sequence shown in SEQ ID NO. 1 and the monoclonal antibody that recognizes the amino acid region at positions 5 to 13 in the amino acid sequence shown in SEQ ID NO. 1 are monoclonal antibodies that specifically bind to the hBNP17-24 epitope (the amino acid region at positions 17 to 24 of hBNP: SEQ ID NO. 4) and the hBNP5-13 epitope (the amino acid region at positions 5 to 13 of hBNP: SEQ ID NO. 5) in hBNP, respectively. Here, "specificity" means that in a liquid system in which a protein having the above epitope of hBNP, other protein components not having the above epitope, and the above monoclonal antibody are mixed, the above monoclonal antibody and the other protein components do not undergo an antigen-antibody reaction at a detectable level; or, even if a certain binding reaction or association reaction occurs, only a reaction that is significantly weaker than the antigen-antibody reaction between the above monoclonal antibody and the protein having the above epitope occurs.

[0029] The monoclonal antibody that recognizes the amino acid region of the 17th to 24th position of hBNP and the monoclonal antibody that recognizes the amino acid region of the 5th to 13th position of hBNP can also be combined with the precursor or degradation product of hBNP. The precursor of hBNP is human B-type natriuretic peptide pro (hproBNP). The degradation product of hBNP is not particularly limited as long as it is a degradation product of the amino acid region of the 5th to 24th position in the amino acid sequence of hBNP. The degradation product of hBNP can be, for example, a degradation product obtained by removing the amino acid at the 31st and 32nd positions in hBNP, or a degradation product obtained by removing the amino acid at the 1st and 2nd positions in hBNP.

[0030] The class of the monoclonal antibody is not limited to IgG, and may be IgY, IgM, camel Ig, or Ig NAR. In addition, the antigen-binding fragment of the monoclonal antibody is not particularly limited, and may be Fab, Fab', F(ab')2, or single-chain antibody (scFv).

[0031] For example, animals can be immunized with hBNP or hBNP fragments containing the above epitopes using known immunological methods, and the above monoclonal antibodies can be obtained from hybridomas produced using immunized animal cells. Alternatively, the above monoclonal antibodies can also be produced using genetic recombination techniques such as phage display and yeast surface display. The length of the hBNP fragment used in immunization is not particularly limited, and is preferably 10 amino acids or more, more preferably 13 amino acids or more.

[0032] The sample is not limited as long as it can contain hBNP or its precursor or degradation product, and may be, for example, a biological sample collected from a human or an animal other than a human. The biological sample may be, for example, blood (whole blood), plasma, or serum.

[0033] The process of detecting human B-type natriuretic peptide or its precursor or degradation product in a sample by latex agglutination method using a monoclonal antibody or its antigen-binding fragment recognizing the amino acid region of the 17th to 24th positions of hBNP, and a monoclonal antibody or its antigen-binding fragment recognizing the amino acid region of the 5th to 13th positions of hBNP, can be performed according to the known latex agglutination method. That is, first, a monoclonal antibody or its antigen-binding fragment recognizing the amino acid region of the 17th to 24th positions of hBNP, and a monoclonal antibody or its antigen-binding fragment recognizing the amino acid region of the 5th to 13th positions of hBNP are respectively immobilized on the first latex particle and the second latex particle. Then, after each antibody-immobilized latex particle is blocked using a known blocking agent such as bovine serum albumin (BSA) as needed, the antibody-immobilized latex particles and the sample are mixed in a buffer solution, and the mixed solution is incubated at a temperature at which an antigen-antibody reaction can occur. Therefore, when hBNP or its precursor or degradation product exists in the sample, the antibody-immobilized latex particles aggregate with each other due to the antigen-antibody reaction. Therefore, the presence or absence of hBNP or its precursor or degradation product in the sample can be detected by detecting the presence or absence of the aggregation by known methods such as light irradiation.

[0034] The first latex particles and the second latex particles may be the same or different, and known latex particles may be used. The materials of the first latex particles and the second latex particles are not particularly limited, and may be, for example, polystyrene, polyacrylonitrile, polymethacrylonitrile or polymethyl methacrylate. From the viewpoint of reducing steric hindrance and obtaining sufficient detection sensitivity, the average particle size of the first latex particles and the second latex particles may be, for example, 0.02 to 5 μm, 0.05 to 1 μm or 0.2 to 0.6 μm. In this specification, the average particle size refers to the particle size (i.e., the median particle size) when the cumulative value from the small particle size reaches 50% of the total in the volume-based particle size distribution curve obtained by the dynamic light scattering method.

[0035] The first latex particles immobilized with a monoclonal antibody that recognizes the amino acid region at positions 17 to 24 of hBNP and the second latex particles immobilized with a monoclonal antibody that recognizes the amino acid region at positions 5 to 13 of hBNP can be mixed with the sample at the same time or separately. In the case where these antibody-immobilized latex particles are mixed with the sample separately, one antibody-immobilized latex particle can be mixed with the sample, and after the mixed solution is incubated at a temperature at which an antigen-antibody reaction can occur, another antibody-immobilized latex particle can be mixed with the mixed solution and incubated again at a temperature at which an antigen-antibody reaction can occur.

[0036] The incubation temperature is not particularly limited, and may be, for example, 20 to 37°C, particularly 37°C, 25°C, or 20°C.

[0037] The monoclonal antibody recognizing the 17th to 24th amino acid region of hBNP and the monoclonal antibody recognizing the 5th to 13th amino acid region of hBNP are close to each other in the epitope recognized by each other, but can also be combined with hBNP under the influence of the steric hindrance between the latex particles that are almost immobilized. Therefore, according to the method involved in this aspect, hBNP or its precursor or degradation product can be detected by latex agglutination method under the influence of steric hindrance. In addition, the monoclonal antibody recognizing the 17th to 24th amino acid region of hBNP and the monoclonal antibody recognizing the 5th to 13th amino acid region of hBNP are because they recognize the region outside the terminal region of hBNP, so according to the method involved in this aspect, hBNP or its precursor or degradation product can be detected by latex agglutination method under the influence of the degradation brought by the terminal of hBNP.

[0038] <Composition for detection>

[0039] One aspect of the present invention relates to a composition for detecting hBNP or its precursor or degradation product, comprising the first latex particles and the second latex particles used in the detection method of the above aspect of the present invention, wherein the first latex particles are immobilized with a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region of positions 17 to 24 in the amino acid sequence shown in sequence number 1, and the second latex particles are immobilized with a monoclonal antibody or its antigen-binding fragment that recognizes the amino acid region of positions 5 to 13 in the amino acid sequence shown in sequence number 1. The details of these monoclonal antibodies and the first latex particles and the second latex particles are as described above. The composition involved in this aspect can be a buffer solution containing the above-mentioned antibody-immobilized latex particles. By mixing the composition involved in this aspect with a sample, the hBNP or its precursor or degradation product in the sample can be detected using a latex agglutination method.

[0040] <Test kit>

[0041] The composition involved in the above aspect is a composition comprising a first latex particle and a second latex particle, wherein the first latex particle is immobilized with a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region at positions 17 to 24 in the amino acid sequence shown in sequence number 1; and the second latex particle is immobilized with a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region at positions 5 to 13 in the amino acid sequence shown in sequence number 1, but in another aspect of the present invention, these antibody-immobilized latex particles can be provided in the form of separate reagents. That is, another aspect of the present invention is a kit for detecting hBNP or its precursor or degradation product, which comprises a first latex particle and a second latex particle, wherein the first latex particle is immobilized with a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region at positions 17 to 24 in the amino acid sequence shown in sequence number 1, and the second latex particle is immobilized with a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region at positions 5 to 13 in the amino acid sequence shown in sequence number 1.

[0042] The kit may further contain a buffer solution and the like, and known reagents, materials, instruments, and the like used in the latex agglutination method.

[0043] Example

[0044] <Test Example 1> Epitope mapping of novel antibodies

[0045] Immunization of mice and rabbits

[0046] Peptides 1 to 19 shown in Table 1 were synthesized. For each peptide, various functional groups were used to bind to carrier proteins such as thyroglobulin, KLH (keyhole limpet hemocyanin), OVA (ovalbumin), and BSA in order to improve the immunogenicity. Mice and rabbits were prepared for each peptide bound to a carrier protein, and immunized for 2 months at intervals of 7 to 14 days. As an adjuvant, Sigma Adjuvant System (registered trademark) (manufactured by Merck) was used. Blood was collected over time during the immunization period, and the antibody titer was determined by ELISA (enzyme-linked immunosorbent assay). Individuals with high antibody titers were selected and the spleen was removed.

[0047] [Table 1]

[0048]

[0049] *1: In peptides 1 to 10 and 12 to 18, the amino acid corresponding to the amino acid at position 10 or 26 (cysteine) of hBNP was changed to serine for ease of synthesis.

[0050] Antibody acquisition

[0051] RNA was extracted from the spleen using TRIzol (registered trademark) Plus RNA purification kit (manufactured by Thermo Fisher Scientific), and cDNA was obtained by reverse transcription reaction using SuperScript (registered trademark) III reverse transcriptase (manufactured by Thermo Fisher Scientific). The cDNA obtained was amplified by PCR reaction using antibody gene-specific primers, and the amplified product was inserted into a vector to obtain an antibody gene library. Using the library and hBNP immobilized microbeads, 4 rounds of panning were implemented using phage display method, and antibodies specifically bound to hBNP were confirmed using ELISA method. The sequences of various antibodies specifically bound to hBNP were inserted into cell expression vectors respectively and expressed in CHO (Chinese hamster ovary) cells, purified using protein A (GE) columns, and 18 full-length antibodies were obtained, and then all epitope identification was performed. It should be noted that the 18 antibodies obtained are basically derived from individuals immunized with peptide 19.

[0052] Identification of epitopes

[0053] The epitope of the obtained antibody was confirmed as follows. First, biotinylated peptides 1 to 18 were synthesized (commissioned to JPT Peptide Technologies) and immobilized on microbeads that can be distinguished from each other (LumAvidin (registered trademark) microspheres manufactured by Luminex). 500 of each peptide-immobilized microbeads were added to each well of a polypropylene microplate, and one antibody was added to one well at a final concentration of 1 μg / mL. After incubating the microplate at 37°C for 1 hour, the supernatant was removed using a magnetic stand and the microplate was washed. R-phycoerythrin-labeled goat anti-mouse IgG or goat anti-rabbit IgG was added as a detection antibody and incubated at 37°C for 1 hour. After removing the supernatant using a magnetic stand and washing the microplate, the fluorescence of R-phycoerythrin was measured using Bio-Plex. The results of epitope mapping of one of the antibodies derived from mice immunized with peptide 19 are shown. Figure 1 .

[0054] The peptide containing the amino acids 17 and 24 of hBNP (peptides 10 to 17) showed significantly more antibody binding than the peptide not containing these amino acids, suggesting that the antibody specifically recognizes the amino acid region 17 to 24 of hBNP.

[0055] <Test Example 2> Evaluation of the influence of steric hindrance

[0056] Various anti-hBNP antibody solutions were mixed with polystyrene microbeads (average particle size: 0.3 μm), respectively, and reacted at 4°C overnight to obtain antibody-immobilized microbeads. As antibodies, an antibody that recognizes the amino acid region of hBNP at positions 5 to 13, an antibody that recognizes the amino acid region of hBNP at positions 17 to 24, and an antibody that recognizes the amino acid region of hBNP at positions 14 to 20 were used. After further adding BSA to each antibody-immobilized microbead for blocking, the microbeads immobilized with the antibody that recognizes the amino acid region of hBNP at positions 5 to 13 and the microbeads immobilized with the antibody that recognizes the amino acid region of hBNP at positions 17 to 24 or 14 to 20 were suspended in a buffer solution. Synthetic hBNP (produced by Prospec) diluted with PBS to 10 ng / mL was added to the dilution buffer and allowed to stand at 37°C for 5 minutes, then mixed with the antibody-immobilized microbead suspension and reacted at 37°C for 5 minutes, and the latex agglutination reaction was detected by irradiating 635 nm light. The results are shown in Figure 2 .

[0057] Figure 2 (A) shows the results using an antibody pair that recognizes the amino acid regions at positions 5 to 13 and 17 to 24 of hBNP. Figure 2 (B) is the result of using an antibody pair that recognizes the 5th to 13th and 14th to 20th amino acid regions of hBNP. When using an antibody pair that recognizes the 5th to 13th and 17th to 24th amino acid regions, the scattering intensity of 635nm light increases over time, while in contrast, when using an antibody pair that recognizes the 5th to 13th and 14th to 20th amino acid regions, the scattering intensity only rises slightly. This result shows that when using an antibody pair that recognizes the 5th to 13th and 17th to 24th amino acid regions, no steric hindrance is formed between the antibody-immobilized latex particles, and the latex reaction proceeds. In contrast, when using an antibody pair that recognizes the 5th to 13th and 14th to 20th amino acid regions, the latex agglutination reaction is hindered due to steric hindrance. It should be noted that the affinity of the antibody recognizing the amino acid region at positions 14 to 20 and the antibody recognizing the amino acid region at positions 17 to 24 for hBNP was confirmed by Biacore (registered trademark) 8K (manufactured by Cytiva) to be 2.4×10 -10 M and 2.41×10 -10 M, it can be considered that the difference in agglutination is not caused by the difference in affinity.

[0058] <Test Example 3> Evaluation of the influence of hBNP degradation

[0059] Various anti-hBNP antibody solutions were mixed with polystyrene microbeads (average particle size: 0.3 μm) and reacted overnight at 4°C to obtain antibody-immobilized microbeads. As antibodies, antibodies that recognize the 5th to 13th amino acid region of hBNP, antibodies that recognize the 17th to 24th amino acid region of hBNP, and antibodies that recognize the 27th to 32nd amino acid region of hBNP were used. After further adding BSA to each antibody-immobilized microbead for blocking, microbeads immobilized with antibodies that recognize the 5th to 13th amino acid region of hBNP and microbeads immobilized with antibodies that recognize the 17th to 24th or 27th to 32nd amino acid region of hBNP were suspended in a buffer. Synthetic hBNP (produced by Prospec) diluted with plasma (produced by Hytest) from which hBNP was removed were added to a dilution buffer and reacted at 37°C for 5 minutes, then mixed with the antibody-immobilized microbead suspension and reacted at 37°C for 5 minutes, and latex agglutination reaction was detected by irradiation with 730 nm light (day 1). In addition, on the first day, synthetic hBNP diluted with hBNP-depleted plasma (manufactured by Hytest) was left to stand overnight at 4°C, and the synthetic hBNP was added to the dilution buffer and subjected to latex agglutination reaction as described above (the second day). The results are shown in Figure 3 .

[0060] Figure 3 In the figure, the scattering intensity is shown as the difference between the scattering intensity at 0 minute after the start of the reaction and the scattering intensity at 5 minutes after the start of the reaction. Figure 3 (A) shows the results using an antibody pair that recognizes the amino acid regions at positions 5 to 13 and 17 to 24 of hBNP. Figure 3 (B) is the result of using an antibody pair that recognizes the amino acid regions of positions 5 to 13 and 27 to 32 of hBNP. When an antibody pair that recognizes the amino acid regions of positions 5 to 13 and 17 to 24 was used, latex agglutination occurred on both the first and second days, whereas when an antibody pair that recognizes the amino acid regions of positions 5 to 13 and 27 to 32 was used, latex agglutination occurred only on the first day, and no latex agglutination occurred on the second day. This result shows that the terminal of hBNP stored overnight in plasma is degraded, and the antibody pair that recognizes the amino acid regions of positions 5 to 13 and 17 to 24 can detect the hBNP whose terminal is degraded, whereas the antibody pair that recognizes the amino acid regions of positions 5 to 13 and 27 to 32 cannot detect the hBNP whose terminal is degraded.

Claims

1. A method for detecting human B-type natriuretic peptide or its precursor or degradation product in a sample, the method comprising the following steps: Using a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region at positions 17 to 24 in the amino acid sequence shown in SEQ ID NO: 1, and a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region at positions 5 to 13 in the amino acid sequence shown in SEQ ID NO: 1, human B-type natriuretic peptide or a precursor or degradation product thereof in a sample is detected by a latex agglutination method, in, The precursor of human B-type natriuretic peptide is pro-human B-type natriuretic peptide, and the degradation product of human B-type natriuretic peptide is a degradation product containing the 5th to 24th amino acid region in the amino acid sequence shown in SEQ ID NO:

1.

2. A composition for detecting human B-type natriuretic peptide or its precursor or degradation product, comprising: First latex particles immobilized with a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region from positions 17 to 24 in the amino acid sequence of SEQ ID NO: 1; and The second latex particles have immobilized thereon a monoclonal antibody or an antigen-binding fragment thereof that recognizes the region of amino acids 5 to 13 in the amino acid sequence shown in SEQ ID NO: 1, in, The precursor of human B-type natriuretic peptide is pro-human B-type natriuretic peptide, and the degradation product of human B-type natriuretic peptide is a degradation product containing the 5th to 24th amino acid region in the amino acid sequence shown in SEQ ID NO:

1.

3. A kit for detecting human B-type natriuretic peptide or its precursor or degradation product, comprising: First latex particles immobilized with a monoclonal antibody or an antigen-binding fragment thereof that recognizes the amino acid region from positions 17 to 24 in the amino acid sequence of SEQ ID NO: 1; and The second latex particles have immobilized thereon a monoclonal antibody or an antigen-binding fragment thereof that recognizes the region of amino acids 5 to 13 in the amino acid sequence shown in SEQ ID NO: 1, in, The precursor of human B-type natriuretic peptide is pro-human B-type natriuretic peptide, and the degradation product of human B-type natriuretic peptide is a degradation product containing the 5th to 24th amino acid region in the amino acid sequence shown in SEQ ID NO:1.